Olin Slashes Q4 Adjusted EBITDA Outlook by ~44% Due to Operational Issues and Weak Demand
summarizeSummary
Olin Corporation revised its Q4 2025 adjusted EBITDA outlook downward by approximately 44% due to operational issues and lower chlorine demand. The new guidance is $67 million, significantly below the prior range of $110 million to $130 million.
check_boxKey Events
-
Revised Q4 2025 Adjusted EBITDA Outlook
Olin Corporation now expects fourth quarter 2025 adjusted EBITDA to be approximately $67 million, a significant reduction from its previous outlook of $110 million to $130 million.
-
Operational Challenges Cited
The earnings shortfall is primarily attributed to an extended planned maintenance turnaround, unplanned downtime at its Freeport, Texas operations, and an interruption of raw material supply by a third party.
-
Weak Chlorine Demand
Lower-than-expected pipeline chlorine demand also contributed to the revised outlook, particularly impacting the Chlor Alkali Products and Vinyls business.
-
Freeport Operations Normalized
CEO Ken Lane noted that the Freeport, Texas site has returned to normal operations, with the company focusing on cost reduction and its value-first commercial approach.
auto_awesomeAnalysis
Olin Corporation has significantly lowered its adjusted EBITDA guidance for the fourth quarter of 2025, now expecting approximately $67 million compared to the previous range of $110 million to $130 million. This substantial reduction, primarily impacting the Chlor Alkali Products and Vinyls business, is a material negative development. The combination of operational issues, including extended maintenance and unplanned downtime, alongside weaker chlorine demand, indicates challenges in a key segment. While the company states its Freeport site has returned to normal operations, the magnitude of the miss for the past quarter is likely to weigh on investor sentiment.
At the time of this filing, OLN was trading at $22.56 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $17.66 to $34.76. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.